Liminal BioSciences Inc. PFSCF

Primary Symbol: LMNL

Healthcare Biotechnology

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.

NDAQ:LMNL - Post by User

Liminal BioSciences Inc. > super secret stuff

<< Previous

Bullboard Posts

Next >>

Comment by stockbuphoonon May 18, 2021 9:25am

54 Views

Post# 33221031

RE:RE:super secret stuff

Newcamo/Realstocky (same guy behind both boardnames - he should use Pinocchio),

Directly from Press Release - Liminal could receive up to 70% of net proceeds from sale of Priority Review Voucher for which it is potentially eligible with possible FDA approval for Ryplazim®

"Potentially eligible" is not guaranteed...... nothing was granted by FDA. Possible FDA approval is not a green light for Ryplazim. You really have a difficult time with English.

Liminal changed the manufacturing process requiring new information so FDA pushed back PDUFA date by 3 months and could easily be delayed again similar to other PDUFA dates at this time.

Newcamo wrote:
the voucher is pretty much garanteed, it was GRANTED already by the FDA.... and it will again with a green light for riplazym.

worth 120m$...we get 70%.....u make the math:)

+ the rest, 17M+5M....more than 100M$ worth

realstocky wrote:

Through its’ US subsidiary, Prometic Biotherapeutics Inc., the Company has resubmitted a BLA in September 2020 with the FDA seeking approval to treat patients with C-PLGD. The FDA confirmed that the resubmission is a complete, Class 2 response to the complete response letter issued in 2018 and has provided a Prescription Drug User Fee Act (“PDUFA”) target action date of June 5, 2021.

Ryplazim® has previously been granted Orphan Drug and Rare Pediatric Disease Designations by the FDA for the treatment of congenital plasminogen deficiency. ====>voucher:)